Cargando…
Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway
BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on ather...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576642/ https://www.ncbi.nlm.nih.gov/pubmed/34790723 http://dx.doi.org/10.21037/atm-20-8106 |
_version_ | 1784595916401934336 |
---|---|
author | Ma, Chun-Yan Shi, Xiao-Yun Wu, Ya-Ru Zhang, Yue Yao, Yu-Hong Qu, Hui-Lin Zhang, Wei Guo, Yuan-Lin Xu, Rui-Xia Li, Jian-Jun |
author_facet | Ma, Chun-Yan Shi, Xiao-Yun Wu, Ya-Ru Zhang, Yue Yao, Yu-Hong Qu, Hui-Lin Zhang, Wei Guo, Yuan-Lin Xu, Rui-Xia Li, Jian-Jun |
author_sort | Ma, Chun-Yan |
collection | PubMed |
description | BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE(-/-) mice. METHODS: The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE(-/-) mice with normal diet), group 3 [ApoE(-/-) mice with high-fat diet (HFD)], group 4 (ApoE(-/-) mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE(-/-) mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined. RESULTS: Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE(-/-) mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. CONCLUSIONS: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE(-/-) mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway. |
format | Online Article Text |
id | pubmed-8576642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-85766422021-11-16 Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway Ma, Chun-Yan Shi, Xiao-Yun Wu, Ya-Ru Zhang, Yue Yao, Yu-Hong Qu, Hui-Lin Zhang, Wei Guo, Yuan-Lin Xu, Rui-Xia Li, Jian-Jun Ann Transl Med Original Article BACKGROUND: It has been demonstrated that berberine (BBR), a kind of alkaloid derived from Chinese herbal medicine, has multiple pharmacological effects on human’s diseases including anti-atherosclerosis action. However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. The present study aimed to investigate potential mechanisms of anti-atherosclerosis by BBR using ApoE(-/-) mice. METHODS: The eight-week mice were divided into five groups: group 1 (wild type C57BL/6J mice with normal diet), group 2 (ApoE(-/-) mice with normal diet), group 3 [ApoE(-/-) mice with high-fat diet (HFD)], group 4 (ApoE(-/-) mice with HFD, and treatment with low dose BBR of 50 mg/kg/d), and group 5 (ApoE(-/-) mice with HFD, and treatment with high dose BBR of 100 mg/kg/d). After a 16-week treatment, the blood sample, aorta and liver were collected for lipid analysis, hematoxylin-eosin (HE) or oil red O staining, and Western blotting respectively. Besides, HepG2 Cells were cultured and treated with different concentrations of BBR (0, 5, 25 and 50 µg/mL) for 24 hours. Subsequently, cells were collected for real-time PCR or western blotting assays. Finally, the expression levels of PCSK9, LDL receptor (LDLR), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1), and scavenger receptor class B type I (SR-BI) were examined. RESULTS: Fifty mg/kg/d and 100 mg/kg/d of BBR decreased total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) level. Moreover, BBR reduced aorta atherosclerotic plaque, and ameliorated lipid deposition in ApoE(-/-) mice fed with HFD. Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. CONCLUSIONS: Data indicated that BBR significantly attenuated lipid disorder, reduced aortic plaque formation, and alleviated hepatic lipid accumulation in ApoE(-/-) mice fed with HFD, which was associated with down-regulation of PCSK9 through ERK1/2 pathway. AME Publishing Company 2021-10 /pmc/articles/PMC8576642/ /pubmed/34790723 http://dx.doi.org/10.21037/atm-20-8106 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Ma, Chun-Yan Shi, Xiao-Yun Wu, Ya-Ru Zhang, Yue Yao, Yu-Hong Qu, Hui-Lin Zhang, Wei Guo, Yuan-Lin Xu, Rui-Xia Li, Jian-Jun Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title | Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title_full | Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title_fullStr | Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title_full_unstemmed | Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title_short | Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-/-) mice by down-regulating PCSK9 via ERK1/2 pathway |
title_sort | berberine attenuates atherosclerotic lesions and hepatic steatosis in apoe(-/-) mice by down-regulating pcsk9 via erk1/2 pathway |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576642/ https://www.ncbi.nlm.nih.gov/pubmed/34790723 http://dx.doi.org/10.21037/atm-20-8106 |
work_keys_str_mv | AT machunyan berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT shixiaoyun berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT wuyaru berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT zhangyue berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT yaoyuhong berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT quhuilin berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT zhangwei berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT guoyuanlin berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT xuruixia berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway AT lijianjun berberineattenuatesatheroscleroticlesionsandhepaticsteatosisinapoemicebydownregulatingpcsk9viaerk12pathway |